Esperion Therapeutics ESPR Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Esperion Therapeutics’s reported figures.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's free cash flow?
- Esperion Therapeutics (ESPR) reported free cash flow of -$27.91M in Q1 2026.
- How has Esperion Therapeutics's free cash flow changed year-over-year?
- Esperion Therapeutics's free cash flow decreased by 23.3% year-over-year, from -$22.63M to -$27.91M.
- What is the long-term trend for Esperion Therapeutics's free cash flow?
- Over 2 years (2021 to 2023), Esperion Therapeutics's free cash flow has grown at a -28.3% compound annual growth rate (CAGR), from -$263.81M to -$135.49M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.